Dian Diagnostics Group Co.,Ltd. cancelled the acquisition of 65% stake in Inner Mongolia Fengxin Medical Technology Co., Ltd. from Deqing Heyingfu Investment Management Partnership (Limited Partnership) and Deqing Hejiaxin Investment Management Partnership (Limited Partnership).
May 15, 2017
Share
Zhejiang DIAN Diagnostics Co., Ltd. (SZSE:300244) signed an agreement to acquire 65% stake in Inner Mongolia Fengxin Medical Technology Co., Ltd. from Deqing Heyingfu Investment Management Partnership (Limited Partnership) and Deqing Hejiaxin Investment Management Partnership (Limited Partnership) for approximately CNY 250 million on May 16, 2016. Zhejiang DIAN Diagnostics will acquire 52% stake from Deqing Heyingfu Investment Management Partnership for CNY 202.8 million and will acquire 13% stake from Deqing Hejiaxin Investment Management Partnership (Limited Partnership) for CNY 50.7 million. After the transaction, Zhejiang DIAN Diagnostics Co., Ltd will own 65% stake in Inner Mongolia Fengxin Medical Technology Co., Ltd, Deqing Heyingfu Investment Management Partnership (Limited Partnership) and Deqing Hejiaxin Investment Management Partnership (Limited Partnership) will hold no stake in Inner Mongolia Fengxin Medical Technology Co., Ltd.
Zhejiang DIAN Diagnostics Co., Ltd will use self-raised funds of CNY 253.5 million to acquire 65% stake. Inner Mongolia Fengxin Medical Technology Co., Ltd reported total assets of CNY 138.1 million, total liabilities of CNY 84.31 million, net assets attributable to parent company of CNY 41.25 million, revenues of CNY 176.03 million, operating profit of CNY 39.87 million and net profit of CNY 29.83 million in 2015. On May 16, 2016, the Board of Zhejiang DIAN Diagnostics Co., Ltd. approved the transaction.
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) cancelled the acquisition of 65% stake in Inner Mongolia Fengxin Medical Technology Co., Ltd. from Deqing Heyingfu Investment Management Partnership (Limited Partnership) and Deqing Hejiaxin Investment Management Partnership (Limited Partnership) on May 16, 2017.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Dian Diagnostics Group Co.,Ltd. cancelled the acquisition of 65% stake in Inner Mongolia Fengxin Medical Technology Co., Ltd. from Deqing Heyingfu Investment Management Partnership (Limited Partnership) and Deqing Hejiaxin Investment Management Partnership (Limited Partnership).
DIAN DIAGNOSTICS GROUP CO.,LTD. 
